Anupam Rama

Ben Burnett

Charles Zhu

Joel Beatty

Maury Raycroft

Tim Chiang

Zegbeh Jallah

- IDEAYA Biosciences announced a partnership with **CRISPR Therapeutics (CRSP)** for the ex-U.S. commercialization of **Darovasertib**, providing capital and enabling focus on the U.S. launch.  **[1676725_tx_379121_0]** **[1676725_tx_379121_1]** **[1676725_tx_379121_8]** 
- The company is preparing for its 10-year anniversary R&D day on **September 8**, where it will provide **three clinical data updates**, including new vision loss data for Darovasertib in the neoadjuvant setting.  **[1676725_tx_379121_0]** **[1676725_tx_379121_5]** **[1676725_tx_379121_6]** 
- IDEAYA will present data for its **DLL3 ADC** program from over **70 patients** at the World Conference on Lung Cancer this weekend, with a target confirmed response rate of **60%** across all lines and a PFS of **six months plus**.  **[1676725_tx_379121_1]** **[1676725_tx_379121_2]** **[1676725_tx_379121_3]** 
- The timeline for the pivotal PFS interim data readout for **Darovasertib** in the metastatic setting has been adjusted to **year-end 2025 or Q1 2026** due to event tracking.  **[1676725_tx_379121_6]** **[1676725_tx_379121_7]** 
- IDEAYA has a **long cash runway into 2030** and plans to have **nine programs in the clinic by year-end**, with Darovasertib, MAT2A, and DLL3 as top priorities.  **[1676725_tx_379121_0]** **[1676725_tx_379121_8]** **[1676725_tx_379121_9]**

IDEAYA Biosciences (IDYA)